The use of inhaled anticholinergics in chronic obstructive pulmonary disease: is there cause for concern of cardiovascular safety?
McIvor
R Andrew
RA
D000280:Administration, Inhalation; D001993:Bronchodilator Agents / Q000008:administration & dosage; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology; D018680:Cholinergic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000453:epidemiology; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012602:Scopolamine Derivatives / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D000069447:Tiotropium Bromide
D001993:Bronchodilator Agents; D018680:Cholinergic Antagonists; D012602:Scopolamine Derivatives; D000069447:Tiotropium Bromide